Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Watch Anglo American (AAL) by Cliff D'Arcy in The Motley Fool
- Avoid ActiveOps (AOM) by Steve Moore in ShareProphets
- Overweight Relx plc (REL) by JP Morgan
- Avoid SRT Marine Systems (SRT) by Steve Moore in ShareProphets
- Sell WPP (WPP) by UBS
- Buy NextEnergy Solar Fund Limited Red (NESF) by Gaurav Sharma in The Motley Fool
- Buy Octopus Renewables Infrastructure Trust (ORIT) by Gaurav Sharma in The Motley Fool
- Buy The Renewables Infrastructure Group Limited (TRIG) by Gaurav Sharma in The Motley Fool
- Buy Aviva (AV.) by Christopher Ruane in The Motley Fool
- Buy Legal & General Group (LGEN) by Christopher Ruane in The Motley Fool
- Buy Persimmon (PSN) by Paul Summers in The Motley Fool
- Hold Anglo American (AAL) by DZ Bank
- Buy Unilever (ULVR) by Stephen Wright in The Motley Fool
- Neutral Unilever (ULVR) by Goldman Sachs
- Buy British American Tobacco (BATS) by Charlie Keough in The Motley Fool
- Sector Perform Unilever (ULVR) by RBC Capital
- Buy Anglo Asian Mining (AAZ) by Hot Stock Rockets in ShareProphets
- Buy Croda International (CRDA) by UBS
- Avoid Videndum (VID) by Steve Moore in ShareProphets
- Buy Reckitt Benckiser Group (RKT) by DZ Bank
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 59 open tips for Shield Therapeutics (STX)
| Latest Bid : 1.20p | Latest Ask : 1.25p |
| High Today : 1.32p | Low Today : 1.06p |
| This Years High : 12.50p | This Years Low : 1.06p |
| Volume : 8,923,337 | MKT Cap : £9.78M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2019-11-04 08:30:00 04/11/2019 | -95.59% |
| Buy | Sabah Meddings | Premium Only | 2019-11-03 10:40:00 03/11/2019 | -95.60% |
| Corporate | FinnCap | Premium Only | 2019-10-23 10:55:00 23/10/2019 | – |
| Buy | Peel Hunt | Premium Only | 2019-10-22 15:10:00 22/10/2019 | -95.62% |
| Buy | Peel Hunt | Premium Only | 2019-10-02 09:25:00 02/10/2019 | -95.05% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 1.20p | Latest Ask : 1.25p |
| High Today : 1.32p | Low Today : 1.06p |
| This Years High : 12.50p | This Years Low : 1.06p |
| Volume : 8,923,337 | MKT Cap : £9.78M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2019-11-04 08:30:00 04/11/2019 | -95.59% |
| Buy | Sabah Meddings | Premium Only | 2019-11-03 10:40:00 03/11/2019 | -95.60% |
| Corporate | FinnCap | Premium Only | 2019-10-23 10:55:00 23/10/2019 | – |
| Buy | Peel Hunt | Premium Only | 2019-10-22 15:10:00 22/10/2019 | -95.62% |
| Buy | Peel Hunt | Premium Only | 2019-10-02 09:25:00 02/10/2019 | -95.05% |